[go: up one dir, main page]

ZA200203901B - Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases. - Google Patents

Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases. Download PDF

Info

Publication number
ZA200203901B
ZA200203901B ZA200203901A ZA200203901A ZA200203901B ZA 200203901 B ZA200203901 B ZA 200203901B ZA 200203901 A ZA200203901 A ZA 200203901A ZA 200203901 A ZA200203901 A ZA 200203901A ZA 200203901 B ZA200203901 B ZA 200203901B
Authority
ZA
South Africa
Prior art keywords
formula
compound
group
use according
salkyl
Prior art date
Application number
ZA200203901A
Other languages
English (en)
Inventor
Paul Howard Ripley
Erich Zeisl
Stefan Horkovics-Kovats
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8239432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200203901(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200203901B publication Critical patent/ZA200203901B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017Non-human animal skin, e.g. pour-on, spot-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200203901A 1999-11-22 2002-05-16 Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases. ZA200203901B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123095 1999-11-22

Publications (1)

Publication Number Publication Date
ZA200203901B true ZA200203901B (en) 2003-09-23

Family

ID=8239432

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203901A ZA200203901B (en) 1999-11-22 2002-05-16 Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases.

Country Status (22)

Country Link
US (1) US6852756B1 (es)
EP (1) EP1231915B1 (es)
JP (1) JP3892298B2 (es)
KR (1) KR100529660B1 (es)
CN (1) CN100344281C (es)
AR (1) AR026523A1 (es)
AT (1) ATE289196T1 (es)
AU (1) AU764451B2 (es)
BR (1) BR0015722A (es)
CA (1) CA2386685C (es)
CO (1) CO5261531A1 (es)
DE (1) DE60018200T2 (es)
DK (1) DK1231915T3 (es)
ES (1) ES2237495T3 (es)
HK (1) HK1052643B (es)
MX (1) MXPA02005149A (es)
NZ (1) NZ518348A (es)
PT (1) PT1231915E (es)
RU (1) RU2264812C2 (es)
TW (1) TWI260220B (es)
WO (1) WO2001037828A1 (es)
ZA (1) ZA200203901B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1399128T3 (da) 2001-06-15 2007-01-08 Innovent Technology Ltd Sammensætning til behandling af sygdomme, der angriber dyrs hove/klove
CO5390081A1 (es) 2001-11-28 2004-04-30 Novartis Ag Compuestos organicos
ES2335284T3 (es) 2003-09-03 2010-03-24 Glaxo Group Limited Nuevo procedimiento para preparar derivados de pleuromutilina.
GB0504314D0 (en) 2005-03-02 2005-04-06 Glaxo Group Ltd Novel polymorph
EP1808431A1 (en) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin derivatives and their use as pharmaceutical
CN102415989A (zh) * 2011-09-30 2012-04-18 上海恒丰强动物药业有限公司 盐酸沃尼妙林溶液剂及其制备方法
CA3043287A1 (en) * 2016-11-09 2018-05-17 Provita Eurotech Ltd Antimicrobial formulations for the treatment of veterinary hoof infections
GB201715122D0 (en) * 2017-09-19 2017-11-01 Omnipharm Dev Ltd Topical anti-infective formulation
KR102098289B1 (ko) * 2018-04-11 2020-04-07 경북대학교 산학협력단 발네물린을 유효성분으로 함유하는 골 질환 예방 또는 치료용 조성물
CN109431980A (zh) * 2018-12-27 2019-03-08 山东齐发药业有限公司 一种用于治疗动物皮肤细菌感染的羟啶妙林软膏剂及其制备方法
CN114366732B (zh) * 2022-02-23 2023-08-18 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 泰妙菌素在制备用于治疗银屑病的药物中的应用
CN117223712B (zh) * 2023-09-19 2024-08-02 贵州大学 一种截短侧耳素可湿性粉剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT301752B (de) * 1969-07-21 1972-09-25 Biochemie Gmbh Verfahren zur Herstellung neuer Pleuromutilin-Derivate
DE2614841A1 (de) 1976-04-06 1977-10-20 Bayer Ag Neue pour-on-formulierungen von anthelmintika
EP0153277B1 (de) * 1984-02-17 1987-08-26 Sandoz Ag Neue Pleuromutilinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
AT400674B (de) * 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
GB9614017D0 (en) * 1996-07-04 1996-09-04 Biochemie Gmbh Organic compounds
GB9807503D0 (en) * 1998-04-07 1998-06-10 Smithkline Beecham Plc Use

Also Published As

Publication number Publication date
CN100344281C (zh) 2007-10-24
BR0015722A (pt) 2002-07-23
AR026523A1 (es) 2003-02-12
PT1231915E (pt) 2005-07-29
KR20020053876A (ko) 2002-07-05
KR100529660B1 (ko) 2005-11-21
CO5261531A1 (es) 2003-03-31
ATE289196T1 (de) 2005-03-15
RU2002116252A (ru) 2004-01-20
ES2237495T3 (es) 2005-08-01
DE60018200T2 (de) 2006-01-12
WO2001037828A1 (en) 2001-05-31
HK1052643B (zh) 2008-03-14
DE60018200D1 (de) 2005-03-24
CA2386685C (en) 2009-05-19
DK1231915T3 (da) 2005-05-02
JP3892298B2 (ja) 2007-03-14
CN1391472A (zh) 2003-01-15
JP2003514856A (ja) 2003-04-22
MXPA02005149A (es) 2002-11-07
NZ518348A (en) 2003-11-28
AU2836501A (en) 2001-06-04
EP1231915B1 (en) 2005-02-16
TWI260220B (en) 2006-08-21
AU764451B2 (en) 2003-08-21
CA2386685A1 (en) 2001-05-31
RU2264812C2 (ru) 2005-11-27
US6852756B1 (en) 2005-02-08
EP1231915A1 (en) 2002-08-21
HK1052643A1 (en) 2003-09-26

Similar Documents

Publication Publication Date Title
CA2386685C (en) Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases
RU2124364C1 (ru) Эндопаразитицидное средство
IE44700B1 (en) Acaricidal treatment
JP2012107024A (ja) 殺内部寄生虫剤
US20240216268A1 (en) Topical composition for the control of pain in animals
JPH0239487B2 (es)
JPWO2014163030A1 (ja) 馬の炎症治療のための製剤
US4336262A (en) Pour-on veterinary anthelmintic
ES2991426T3 (es) Composición para uso en el tratamiento de la enfermedad de la fiebre actosa (FMD), boquera (ORF), picornavirus, parapoxvirus y una enfermedad patógena que causa lesiones de viruela
RU2280458C1 (ru) Противовоспалительная мазь
EP0080281A1 (en) Therapeutic use of allantoin-formaldehyde condensation products
RU2519085C1 (ru) Противопаразитарное средство для сельскохозяйственных животных
RU2140737C1 (ru) Средство для профилактики и лечения паразитарных заболеваний животных
RU2091074C1 (ru) Эмульсия для лечения метритов крупного рогатого скота (варианты)
RU2058782C1 (ru) Препарат для лечения и профилактики мастита крупного рогатого скота в сухостойный период
RU2014835C1 (ru) Способ лечения фасциолеза и дикроцелиоза сельскохозяйственных животных
MXPA04009186A (es) El uso de derivados de hidroxipiridona en curacion de heridas.
RU2058781C1 (ru) Препарат для лечения и профилактики мастита крупного рогатого скота в сухостойный период
RU2276983C2 (ru) Цестодоцидная композиция для животных
JPS60208907A (ja) 毛髪成長刺激剤
GB1583802A (en) Use of moxnidazole for combating diseases in the veterinary field
HU204191B (en) Process for producing veterinal solution composition for treating deseases of hoof and ulcerous and inflamed wounds
AU2008201426A1 (en) Anthelmintic compositions